Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021


ABSTRACT

Objective To understand community seroprevalence of SARS-CoV-2 in children and adolescents. This is vital to understanding the susceptibility of this cohort to COVID-19 and to inform public health policy for disease control such as immunisation.

Design We conducted a community-based cross-sectional seroprevalence study in participants aged 0–18 years old recruiting from seven regions in England between October 2019 and June 2021 and collecting extensive demographic and symptom data. Serum samples were tested for antibodies against SARS-CoV-2 spike and nucleocapsid proteins using Roche assays processed at UK Health Security Agency laboratories. Prevalence estimates were calculated for six time periods and were standardised by age group, ethnicity and National Health Service region.

Results Post-first wave (June–August 2020), the (anti-spike IgG) adjusted seroprevalence was 5.2%, varying from 0.9% (participants 10–14 years old) to 9.5% (participants 5–9 years old). By April–June 2021, this had increased to 19.9%, varying from 13.9% (participants 0–4 years old) to 32.7% (participants 15–18 years old). Minority ethnic groups had higher risk of SARS-CoV-2 seropositivity than white participants (OR 1.4, CI 1.0 to 2.0), and those in children have predominantly tested samples obtained opportunistically in a clinical context or in school-based populations, both of which bring potential biases.

In response to the COVID-19 pandemic, the Oxford Vaccine Group, in collaboration with UK Health Security Agency, modified an existing sero-prevalence pilot study (‘What’s the STORY?’) evaluating serum antibody concentrations against vaccine preventable diseases to determine anti-SARS-CoV-2
serum antibodies across England. This study was funded by the National Institute for Health Research.

Here we report SARS-CoV-2 sero-epidemiology in participants aged 0–18 years old in England prior to widespread immunisation in this population from samples collected from the end of 2019 through to mid-2021. In addition, we explore potential risk factors for COVID-19 seropositivity and the utility of symptom-based indicators of infection.

METHODS

Study design
This was a cross-sectional seroprevalence study recruiting participants from 13 sites distributed across all seven National Health Service (NHS) regions in England, conducted between October 2019 and June 2021. Eleven sites recruited participants aged 0–24 years (data for those aged 0–18 years old presented here) from postcode districts representative of their NHS region in terms of deprivation (defined by 2019 Index of Multiple Deprivation (IMD)6) and urban/rural ratio as identified by local knowledge (online supplemental table 1). IMD measures deprivation available at a Lower Super Output Area (LSOA, an area with an average population of 1500) level and based on seven domains of deprivation (income, employment, education, health, crime, barriers to housing and services and living environment).2 Invitation letters were sent through Docmail (a UK General Data Protection Regulation compliant bulk mailing system) from extracts provided by either NHS Digital7 or Child Health Information Systems (CHIS)8 databases, in addition to social media campaigns. Two sites recruited participants aged 0–19 years old via social media campaigns and were not postcode restricted. Potential participants and their families were invited to visit the study website (https://whatsthestory.web.ox.ac.uk) for additional information and local teams’ contact details.

Due to emerging differences in COVID-19 infection in minority ethnic groups in adult studies,9,10 an enhanced recruitment strategy for ethnic minority groups started in January 2021. Multiple strategies (targeted mail outs, social media, text messages from general practitioners (GPs), pharmacy advertising) were used.

Data collection
Participants or their parent/guardian recorded (electronically or on a paper form) responses to questions regarding the participant’s demographics, as well as selected questions from the UK Census 2011 relating to accommodation and employment, and from the Family Affluence Scale iii (FASiii)10 relating to socio-economic status. These data were collected using the Research Electronic Data capture system, V10.6.13. Responses to the individual-level UK Census11 and FASiii10 questions for those aged 0–13 years old (scored out of a total of 13)12 were used to assess the appropriateness of the LSOA-level IMD and the Income Deprivation Affecting Children Index (IDACI), the proportion of children aged 0–15 years living in income-deprived families scores for our study.

In response to the pandemic, from February 2020, questionnaires were adapted to ask if participants and/or their household had experienced any potential COVID-19 symptoms (fever, dry cough, shortness of breath, muscle aches, feeling tired, loss of appetite). This was further adapted in July 2020 to enable description of which symptoms participants and household contacts had experienced, self-reported results of relevant PCR or antibody testing. Those participants who were already enrolled were approached retrospectively to collect missing data from the updated questionnaire (online supplemental appendix 1). Receipt of a COVID-19 vaccine and vaccination date were recorded either at the visit from personal written documentation or afterwards from GP or CHIS records.

Measurement of serum antibodies
Blood samples were analysed for SARS-CoV-2–specific antibody responses using the Roche Elecsys Anti-SARS-CoV-2 serological assays for the detection of anti-SARS-CoV-2 IgG spike protein (RocheS) and nucleocapsid (RocheN) antibodies in serum/plasma samples using electrochemiluminescent immunoassays.13,14 Both assays report high sensitivity and specificity (online supplemental table 2).15,16

Statistical analysis

Sero-prevalence
The unweighted observed prevalence for RocheS and RocheN separately was calculated as n+/N for children aged 0–18 years, where n+ was the number of individuals who tested positive, and N was the total number of individuals tested with an available result. Unweighted prevalence was calculated for each of six time periods (figure 1).15,16 Overall, by age group (0–4 years, 5–9 years, 10–14 years, 15–18 years) and by region. Prevalence estimates for each time period were standardised by age group, ethnicity and NHS region using the STATA stdize command. Population estimates of demographic variables were determined from NewETHPOP-Evaluation, Revision and Extension of Ethnic Population Projections.17

Risk factors
Age group, sex, NHS region, time period, ethnicity (grouped as white and minority ethnic groups), IMD or Income Deprivation Affecting Children Index (IDACI) deprivation quintile (for comparison) and urban/rural classifications were analysed in univariate and multivariable logistic regression models. A separate model tested the presence of a healthcare worker in the family as a risk factor.

Symptoms
Symptoms associated with seropositivity were explored for participants aged 0–9 years old and 10–18 years old separately to optimise statistical power while allowing discrimination of differences between participants attending early-years and primary school educational settings compared with secondary school and higher education. A backwards stepwise regression approach was applied whereby variables with the highest p value were sequentially excluded and model Akaike Information Criterion (AIC) values were compared until a model with the lowest AIC value had been reached. Sex, a non-significant variable, was included to show it did not influence the model. Highly correlated symptoms were grouped, for example, gastrointestinal symptoms included diarrhoea, vomiting and abdominal pain.

Participants reported to be vaccinated before their visit were excluded from all analyses. Analyses were carried out in Stata V17.18

RESULTS
The study recruited 2963 participants 0–24 years between October 2019 and June 2021, 2542 of whom were aged 0–18 years. Of these, 2540 were COVID-19 vaccine naïve prior to their visit. RocheS and RocheN results were available for 2477 of 2540 (98%) and 2475 of 2540 (97%) participants,
respectively. Of those with ethnicity specified, 17% were non-white ethnic groups (online supplemental tables 3 and 4).

The proportion of children aged 0–15 years in each IMD and IDACI quintile was similar (within 1.5%) for the study overall, and within 10% of their local IMD quintile across the majority of regions with the exception of the North West (<1% in least deprived IMD quintile vs 21% in least deprived IDACI quintile) and South East. Nevertheless, >8% of children aged 0–15 years in the North West had individual-level FASii scores >11 (where 13 is most affluent) (online supplemental table 5). Responses to selected UK Census questions for children aged 0–15 years were generally in agreement with IMD and IDACI quintiles, but did not clearly differentiate between the scoring systems.

In total, 628 of 2477 (25%) were children of healthcare workers.

Comparison of assays
Of the 2472 participants with results for both assays, 218 (9%) were both positive, and 2215 (90%) both negative with 40 (1%) having discordant results (online supplemental figure 1). The majority (35 of 40, 88%) of discordant results were RocheS positive and RocheN negative. Here we report RocheS results (online supplemental materials include RocheN results).

Seroprevalence
Overall seroprevalence, adjusted for age, ethnicity and NHS region, increased over time (figure 1 and online supplemental table 6) from 0 in October 2019–March 2020 to 20% (95% CI 16% to 24%) in April 2021–June 2021. For all age groups, seroprevalence remained relatively stable (10% or below) until September–December 2020, where those aged 15–18 years old increased to 23%, followed by an increase in all age groups from January 2021 onwards. By April–June 2021, the adjusted seroprevalence was 20%, varying from 14% in children aged 0–4 years old to 33% in those aged 15–18 years old (figure 2 and online supplemental table 7).

In June–August 2020, the highest age and ethnicity-adjusted seroprevalence was recorded in London (34%, 95% CI 19% to 49%). In April–June 2021, the highest seroprevalence was in the North West (52%, 95% CI 33% to 71%) (figure 3 and online supplemental table 8).

Presence of symptoms in seropositive participants
Overall, 48% (95% CI 42% to 55%) of seropositive participants reported no symptoms (figure 4 and online supplemental figure 2). Fever was reported in 29% of seropositive participants, and in a univariate analysis was predictive of SARS-CoV-2 positivity in those aged 10–18 years old only (online supplemental figure 3). No solicited symptoms were individually predictive of seropositivity in children aged 0–9 years old.

Backwards stepwise regression demonstrated fever and loss of taste and smell were significant in the older cohort (10–18 years). No symptom clusters were predictive in children 0–9 years old, and fever was of borderline significance in predicting seropositivity (online supplemental table 9).

Risk factor analysis
The risk of a RocheS seropositive result on a univariate analysis was stable across children 0–14 years old with an increased risk
in those 15–18 years old (OR 1.5, 95% CI 1.0 to 2.1, p=0.08), and increase persisting in the multivariable analysis (OR between 1.4 and 1.5, p≤0.05) (table 1 and online supplemental table 10). The North West and London NHS regions showed a higher seropositivity compared with South East (baseline). A higher proportion of children were seropositive living in urban areas than rural areas. Children in minority ethnic groups showed a significantly higher risk in the multivariable analyses compared with their white counterparts (OR 1.4, p=0.04). On univariate analysis, a significant trend towards higher risk of seropositivity in the areas with higher deprivation was seen, however, this was not statistically significant in the multivariable analysis when using either

Figure 2  SARS-CoV-2 seroprevalence (RocheS (anti-SARS-CoV-2 IgG spike protein antibodies) and RocheN (anti-SARS-CoV-2 IgG nucleocapsid antibodies)) by age group and time period October 2019–June 2021 in England, adjusted for National Health Service region and ethnicity. Error bars indicate 95% CI.

Figure 3  SARS-CoV-2 seroprevalence (RocheS (anti-SARS-CoV-2 IgG spike protein antibodies) and RocheN (anti-SARS-CoV-2 IgG nucleocapsid antibodies)) by region and time period October 2019–June 2021 in England, adjusted for age and ethnicity. Error bars indicate 95% CI.
participants aged 15–18 years old had antibodies against SARS-CoV-2 in April–June 2021, prior to immunisation or the further wave of infections in this age group that occurred in Autumn 2021. This study adds to the evidence base regarding paediatric SARS-CoV-2 seroprevalence, building on other studies in England and/or the UK, including SKIDS\(^4\) (recruiting from educational settings) and COVID Warriors\(^3\) (recruiting children of healthcare workers). Together these seroprevalence studies provide estimates of the levels of seropositivity within the paediatric population, vital for modelling of disease susceptibility and immunisation planning, complementing insights gained from repeat cross-sectional community infection surveys such as REACT-\(^1\) and the COVID-19 infection survey.\(^1\)

When comparing studies at similar time points, differences in estimates emerge. In April–August 2020, overall rates of seropositivity in our data were approximately half those of COVID Warriors,\(^3\) likely due to the elevated risk of seropositivity in household members of healthcare workers. In June 2021, our age-adjusted estimates were higher than the SKIDS Study, which reports 11.25% and 12.95% of primary and secondary school pupils being seropositive using oral fluid sampling,\(^21\) compared with 18.9% and 32.7% in similar age groups in our study. This may reflect differences in sensitivity in antibody detection in saliva (75%) vs serum (95.5%).\(^14\)\(^22\) Last, ONS (Office for National Statistics) data in summer 2021 showed a seroprevalence of 47% in participants aged 16–24 years old\(^19\) compared with 32.7% in those aged 15–18 years old in our study, a variance potentially accounted for by higher infection rates observed in those aged 18–24 years old in the period,\(^22\) along with the possibility of vaccine-induced immunity in this older age group.

More consistency is seen when comparing trends over time. The dramatic increase in seropositivity evident in September–December 2020 in participants 15–18 years old, followed by all younger age groups (including those 0–4 years old) in January 2021–March 2021 is consistent with antibody data from SKIDS showing an increase in infection rates in those aged 11–18 years old in September–December 2020.\(^3\) A further increase in seropositivity in participants aged 15–18 years old in April–June 2021 corresponds to the emergence of the delta variant, and associated increase in adolescent (13–17 years old) infections demonstrated in REACT-1 antigen data in May–July 2021.\(^2\) COVID-19 seroprevalence varied across regions, with an early (June–August 2020) increase in London, again consistent with COVID Warriors and REACT Studies,\(^3\) while the striking increase in seropositivity rates in the North West from May to June 2021 is reflected in regional data from the COVID-19 infection survey.

Our data showed a greater than twofold increased risk for participants from a minority ethnic group compared with white participants, which remained elevated in the multivariable analysis (including adjustment for socioeconomic status). This is consistent with the increased risk of SARS-CoV-2 infection from minority ethnic groups reported in the adult and paediatric populations since the first peak of the pandemic in England. Ward et al showed a threefold increase in risk of being antibody positive in the adult black population in England.\(^1\) This trend was also reported by Ladhani et al in primary school children in June 2020.\(^23\) Our data were not powered to look at individual ethnic groups, nevertheless we show that belonging to a minority ethnic group is a significant risk factor in the paediatric population (independent of socioeconomic status and adult-type comorbidities). Of note is that this increased risk became of borderline significance
when the presence of a healthcare worker in the household was included in the multivariable analysis, although this also may reflect the limitations of a smaller dataset. Nevertheless, the increased susceptibility among minority ethnic groups requires further study as to whether it reflects reduced access to healthcare or other social equalities.
Unlike COVID Warriors, we did not demonstrate that gastrointestinal symptoms were predictive of seropositivity. This may reflect a symptomatology specific to ancestral lineages A and B which were in circulation when COVID Warriors collected their initial data, or differing methods of data collection. Of note is that in our study, symptomatology questionnaires were adapted as the study progressed, with some symptoms collected retrospectively creating the potential for recall bias. Furthermore, while the age discrepancy in reporting of anosmia and ageusia is striking, this may reflect difficulties in children <10 years of age communicating these symptoms.

The strengths of this study are that it includes participants aged 0–18 years old and has sampled from all NHS regions in England which allows generalisations to be made to England as a whole. To our knowledge, at the time of publication, this is the only paediatric study in England that has a community-based recruitment strategy with efforts to recruit a representative sample of the region. The study has several limitations, including having been adapted from a pre-pandemic design. One-quarter of participants were children of healthcare workers, which is higher than the general population. Both the RocheS and RocheN assays have primarily been validated in the adult, rather than paediatric population, and there is the possibility that the SARS-CoV-2 nucleocapsid-specific IgG response to infection, and the longevity of that response, may differ in younger age groups. Of note is the increased divergence between RocheS and RocheN assays in later time periods. As participants with known COVID-19 vaccinations (which would lead to a positive RocheS while RocheN remained negative) were excluded from the analysis, and widespread immunisation was not conducted in the relevant age groups during the period studied, this may reflect more rapid waning of RocheN than RocheS, which has been seen in the adult literature.

This study has provided a gold-standard SARS-CoV-2 seroprevalence dataset as part of a unique biobank of serum samples from children and young adults aged 0–24 years with a comprehensive history of immunisation and demography. The willingness of participants and their families to participate in research has created an invaluable resource for understanding COVID-19 and other infectious diseases.

Author affiliations
1Department of Paediatrics, University of Oxford, Oxford, UK
2Statistics, Modelling and Economics Department, Health Protection Agency, London, UK
3Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, UK
4St George’s Vaccine Institute, St George’s University Hospitals NHS Foundation Trust, London, UK
5Academic Unit of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
6NIHR Wellesley Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK
7Department of Paediatrics, Royal Manchester Children’s Hospital, Manchester, UK
8Respiratory Group, University of Manchester, Manchester, UK
9Paediatric Infectious Diseases and Immunology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
10Immunology, Allergy and Infectious Diseases, Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK
11Bradford Neonatology, Bradford Teaching Hospitals NHS Foundation Trust, West Yorkshire, UK
12Paediatric Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK
13School of Life Sciences, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK
14Department of Paediatrics, University Hospitals Plymouth NHS Trust, Plymouth, UK
15Paediatric Immunology and Infectious Diseases, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
16Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
17Section of Paediatrics, Imperial College London, London, UK
18Department of Paediatrics, West Suffolk NHS Foundation Trust, Bury Saint Edmunds, UK
19Vaccine Evaluation Unit, UK Health Security Agency, London, UK
20Virus Reference Department, Public Health England, Colindale, UK

Twitter Stephen Owens @owens_stephen

Acknowledgements The investigators express their gratitude for the contribution of all trial participants.

Collaborators What's the STORY research group: K Bell, Newcastle NHS Trust; C Kennedy, Newcastle NHS Trust; A Bell, Newcastle NHS Trust; C L Coates, Newcastle NHS Trust; S Cruiley, Newcastle NHS Trust; A Davies, Newcastle NHS Trust; S King, Newcastle NHS Trust; D T J Metcalfe, Newcastle NHS Trust; C Reagan, Newcastle NHS Trust; D T J Fabian, Newcastle NHS Trust; R A Sarjeant, Newcastle NHS Trust; C Smith, Newcastle NHS Trust; L B Baxter, Newcastle NHS Trust; E Thompson, Newcastle NHS Trust; R Wane, Bradford Children’s Research Team; R Swinger, Bradford Children’s Research Team; C Bass-Woodcock, Bradford Children’s Research Team; L Ingram, Bradford Children’s Research Team; J Pearce, St George’s Vaccine Institute, St George’s University Hospital NHS Trust/St George’s University of London; C Hulin, St George’s Vaccine Institute, St George’s University Hospital NHS Trust/St George’s University of London; J I Pereira, St George’s Vaccine Institute, St George’s University Hospital NHS Trust/St George’s University of London; H Foile, St George’s Vaccine Institute, St George’s University Hospital NHS Trust/St George’s University of London; F Fox, St George’s Vaccine Institute, St George’s University Hospital NHS Trust/St George’s University of London; E Stefanova, St George’s Vaccine Institute, St George’s University Hospital NHS Trust/St George’s University of London; P Fox, St George’s Vaccine Institute, St George’s University Hospital NHS Trust/St George’s University of London; E Johanns-Baynton, Bristol Vaccine Centre (BCV); E B Burch, Bristol Vaccine Centre (BCV); K Janssens-Baynton, Bristol Vaccine Centre (BCV); Z J Bordan, Bristol Vaccine Centre (BCV); D Ellis, Leeds Teaching Hospitals NHS Trust; R Lidstone-Scott, Leeds Teaching Hospitals NHS Trust; E Storr Plymouth NHS Trust; A Carney Plymouth NHS Trust; S Sharma, Plymouth NHS Trust; N J Oldfield, University of Nottingham Health Service; S Royal, University of Nottingham Health Service; S Selton, University of Nottingham Health Service; D Hammersley, University of Nottingham Health Service; J Wilson, Royal Manchester Children’s Hospital; N Phillips, Royal Manchester Children’s Hospital; F Jennings, Royal Manchester Children’s Hospital; I Mayor, Royal Manchester Children’s Hospital; K Willis, Royal Manchester Children’s Hospital; S Williams, Royal Manchester Children’s Hospital; S Aker, Royal Manchester Children’s Hospital; A Ashworth, Royal Manchester Children’s Hospital; H Dalgleish, Royal Manchester Children’s Hospital; A Wheeler, Royal Manchester Children’s Hospital; S Persand, Imperial College London; S J Burrell, Imperial College London; R Harrison, Sheffield Children’s Hospital NHS Trust; S J Hill, Sheffield Children’s Hospital NHS Trust; S Gormley, Sheffield Children’s Hospital NHS Trust; R Owens, University Hospital Southampton NHS Foundation Trust and University of Southampton; P S Munro, University Hospital Southampton NHS Foundation Trust and University of Southampton.

Contributors MDS, NA, GA and JLB conceived the study, while MDS is the chief investigator. MDS, NA, JLB, GA, MR and HR contributed to the protocol and design of the study. PA, EP, IV, EM, NLD, SM and HR led the implementation of the study. EPG, SNE, SH, CSM, MP, FS, SJO, TL, DPJ, MR, SQ, PT and HC were site leads who contributed to the adaptation of the study design during the SARS-CoV-2 pandemic, to implementation of the study in the context of the pandemic and acquisition of data. KB, EL and RB were responsible for performing laboratory testing. KST and HR conducted the statistical analysis and verified the underlying data under the supervision of NA and MV. HR, KST and MDS drafted the initial version of the paper which was critically reviewed by all other authors for important intellectual content. All other authors contributed to the implementation and data collection. All authors reviewed and approved the final report. MDS is the guarantor.

Funding This research is funded by the National Institute for Health Research (NIHR) Policy Research Programme and the UK Research and Innovation (UKRI) Medical Research Council (PR-R7-0916-22001, CV220-036, CV220-036/1). The research is supported by the NIHR Oxford Clinical Research Facility and Biomedical Research Centre, the NIHR Oxford Biomedical Research Centre and the Oxford NIHR-funded National Immunisation Schedule Evaluation Consortium (PR-R7-0916-22001). The study sponsor is the University of Oxford. The processing of samples was completed by the COVID-19 serology team within Virus Reference Department at UKHSA. CSM is supported by NIHR Manchester BRC.

Competing interests MDS acts on behalf of the University of Oxford as an investigator on studies funded or sponsored by vaccine manufacturers, including
AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune and MCM. He receives no personal financial payment for this work. SNF acts on behalf of University Hospital Southampton National Health Service (NHS) Foundation Trust as an investigator or providing consultative advice, or both, on clinical trials and studies of COVID-19 and other vaccines funded or sponsored by vaccine manufacturers including Janssen, Pfizer, AstraZeneca, GlaxoSmithKline, Novavax, Seqirus, Sanofi, Medimmune, Merck and Valneva. He receives no personal financial payment for this work. MR and EL, through the Immunisation Department, provide vaccine manufacturers (including Pfizer) with post-marketing surveillance reports about pneumococcal and meningococcal disease which the companies are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. PA acts on behalf of the University of Oxford as the director of operations at the Oxford Vaccine Group and has received funding from the Vaccine Taskforce via the NIHR and AstraZeneca.

Patient consent for publication Not required.

Ethics approval This study involves human participants and ethical approval was obtained from the London-Surrey Research Ethics Committee (REC Reference: 19/LO/1040). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement Data are available upon reasonable request. After publication, anonymised individual patient data will be made available upon request to the corresponding author for secondary research, conditional on assurance from the secondary researcher that the proposed use of the data is compliant with the Medical Research Council Policy on Data Sharing regarding scientific quality, ethical requirements, and value for money, and is compliant with the National Institute for Health Research policy on data sharing. A minimum requirement with respect to scientific quality will be a publicly available prespecified protocol describing the purpose, methods, and analysis of the secondary research (eg, a protocol for a Cochrane systematic review), approved by a UK Research Ethics Committee or other similar, approved ethics review body. Participant identifiers will not be passed on to any third party. Data will be available for 5 years after publication.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: http://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Helen Ratcliffe http://orcid.org/0000-0002-4048-1025
Saul N Faust http://orcid.org/0000-0003-3410-7642
Clare S Murray http://orcid.org/0000-0002-8961-8055
Sam J Oddie http://orcid.org/0000-0001-8701-4912
Stephen Owens http://orcid.org/0000-0002-6979-9207
Paul Turner http://orcid.org/0000-0001-9862-5161

REFERENCES

10 Hartley JEK, Levin K, Currie C. A new version of the HBSC Family Affluence Scale - FAS III : Scottish qualitative findings from the international FAS Development Study Child Indicators Research, 2016: 233–45.